Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Targeting integrin beta4 for cancer and anti-angiogenic therapy.

Giancotti FG.

Trends Pharmacol Sci. 2007 Oct;28(10):506-11. Epub 2007 Sep 5. Review.

PMID:
17822782
2.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
3.

Co-opted integrin signaling in ErbB2-induced mammary tumor progression.

Carraway KL 3rd, Sweeney C.

Cancer Cell. 2006 Aug;10(2):93-5. Review.

4.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
5.

From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.

Pang RW, Poon RT.

Oncology. 2007;72 Suppl 1:30-44. Epub 2007 Dec 13. Review.

PMID:
18087180
6.

Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.

Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S.

Princess Takamatsu Symp. 1994;24:162-70. Review.

PMID:
8983073
7.
8.

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.

Tortora G, Ciardiello F, Gasparini G.

Nat Clin Pract Oncol. 2008 Sep;5(9):521-30. doi: 10.1038/ncponc1161. Epub 2008 Jul 1. Review.

PMID:
18594498
9.

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.

Kerbel RS, Viloria-Petit A, Klement G, Rak J.

Eur J Cancer. 2000 Jun;36(10):1248-57. Review.

PMID:
10882863
10.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
11.

EGFR signaling and drug discovery.

Lurje G, Lenz HJ.

Oncology. 2009;77(6):400-10. doi: 10.1159/000279388. Epub 2010 Feb 2. Review.

PMID:
20130423
12.

The roles of integrin β4 in vascular endothelial cells.

Wang L, Dong Z, Zhang Y, Miao J.

J Cell Physiol. 2012 Feb;227(2):474-8. doi: 10.1002/jcp.22769. Review.

PMID:
21465468
13.

Inhibitors of vascular endothelial growth factor in cancer.

Pourgholami MH, Morris DL.

Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):343-7. Review.

PMID:
18855647
14.

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM.

Anticancer Drug Des. 2000 Feb;15(1):29-41. Review.

PMID:
10888034
15.

Molecularly targeted therapy for gastrointestinal cancer.

Wiedmann MW, Caca K.

Curr Cancer Drug Targets. 2005 May;5(3):171-93. Review.

PMID:
15892618
16.

Growth factor signaling in metastasis: current understanding and future opportunities.

Lowery FJ, Yu D.

Cancer Metastasis Rev. 2012 Dec;31(3-4):479-91. doi: 10.1007/s10555-012-9380-x. Review.

PMID:
22706845
17.

MET pathway as a therapeutic target.

Kim ES, Salgia R.

J Thorac Oncol. 2009 Apr;4(4):444-7. doi: 10.1097/JTO.0b013e31819d6f91. Review.

18.

Invasive growth: a MET-driven genetic programme for cancer and stem cells.

Boccaccio C, Comoglio PM.

Nat Rev Cancer. 2006 Aug;6(8):637-45. Review.

PMID:
16862193

Supplemental Content

Support Center